Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
35.47
+1.34 (3.93%)
Jun 26, 2026, 4:00 PM EDT - Market closed
HRMY Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 145.62 | 158.69 | 145.49 | 128.85 | 181.47 | 34.6 |
Depreciation & Amortization | 25.34 | 25.34 | 24.11 | 24.36 | 23.39 | 18.84 |
Stock-Based Compensation | 43.02 | 44.9 | 42.6 | 31.71 | 26.17 | 15.66 |
Other Adjustments | 59.96 | 27.47 | 14.94 | -0.57 | -82.46 | 28.83 |
Change in Receivables | -2.25 | -13.75 | -8.89 | -19.4 | -19.9 | -12.67 |
Changes in Inventories | 1.1 | 1.84 | -1.84 | -1.07 | 0.14 | -0.61 |
Changes in Accounts Payable | 11.14 | 3.95 | -5.38 | 8.95 | 2.79 | -1.56 |
Changes in Accrued Expenses | - | - | - | - | - | 17.26 |
Changes in Other Operating Activities | 58.06 | 99.78 | 8.79 | 46.55 | 12.87 | -1.8 |
Operating Cash Flow | 341.97 | 348.2 | 219.82 | 219.39 | 144.47 | 98.56 |
Operating Cash Flow Growth | 53.58% | 58.40% | 0.20% | 51.86% | 46.58% | - |
Capital Expenditures | -0.18 | -0.31 | -1.15 | -0.31 | -0.17 | -0.3 |
Purchases of Investments | -246.01 | -86.15 | -105.29 | -127.47 | -110.73 | - |
Proceeds from Sale of Investments | 86.79 | 81.06 | 98.53 | 118.31 | 9.07 | - |
Payments for Business Acquisitions | - | - | -33.07 | -36.97 | - | - |
Other Investing Activities | -47 | -34.25 | -26.5 | - | -40 | -100 |
Investing Cash Flow | -225.66 | -39.65 | -67.48 | -46.44 | -141.83 | -100.3 |
Long-Term Debt Issued | - | - | - | 200 | - | 200 |
Long-Term Debt Repaid | -17.5 | -16.25 | -15 | -201.25 | -2 | -200.5 |
Net Long-Term Debt Issued (Repaid) | -17.5 | -16.25 | -15 | -1.25 | -2 | -0.5 |
Issuance of Common Stock | 5.85 | 10.21 | 6.5 | 5.06 | 8.84 | 39.37 |
Repurchase of Common Stock | - | - | - | -100 | - | - |
Net Common Stock Issued (Repurchased) | 5.85 | 10.21 | 6.5 | -94.95 | 8.84 | 39.37 |
Other Financing Activities | -4.26 | -3 | -2.5 | -9.36 | - | -30.45 |
Financing Cash Flow | -15.92 | -9.05 | -11 | -105.55 | 6.84 | 7.42 |
Net Cash Flow | 100.4 | 299.5 | 141.34 | 67.4 | 9.48 | 5.68 |
Free Cash Flow | 341.79 | 347.89 | 218.67 | 219.08 | 144.29 | 98.26 |
Free Cash Flow Growth | -1.75% | 59.09% | -0.19% | 51.82% | 46.85% | - |
FCF Margin | 38.01% | 40.06% | 30.59% | 37.64% | 32.95% | 32.17% |
Free Cash Flow Per Share | 5.83 | 5.94 | 3.78 | 3.63 | 2.36 | 1.66 |
Levered Free Cash Flow | 223.57 | 273.03 | 155.02 | 206.09 | 218.47 | 65.94 |
Unlevered Free Cash Flow | 235.13 | 284.42 | 169.28 | 221.18 | 247.34 | 112.75 |